Español
Nederlands
Italiano
Deutsch
Français
Português
In this section of the page, you will find all the information you need to understand how Pharming Group (PHARM) dividends work. In addition, you will be able to consult the payment date, the ex-dividend date, the last day to be entitled to the payment, the money to be received per share, the yield and any other doubts that may arise.
There is no upcoming dividend defined for Pharming Group.
There is no set last day on which buying Pharming Group shares generates the possibility of earning dividends.
There has been no final dividend for Pharming Group.
Pharming Group N.V., listed in the United States, Germany and the Netherlands under the name PHAR, does not pay dividends to its shareholders.
Join +33,000 investors who get notifications, analysis and news.
Payout Ratio Pharming Group Dividends
The dividend payout ratio, also known as the payout ratio, is an essential indicator for assessing the stability of a company's dividends. This ratio shows what proportion of the company's net profit is used to pay dividends to shareholders.
Dividend payout ratio = Total dividends ÷ Net income
An appropriate payout ratio may vary depending on the industry, the company's growth stage and its financial health.
Dividend calendar of Pharming Group
There is no Dividend Calendar of Pharming Group defined for 2023.
Historical annual dividend yields of Pharming Group
For a company to have growing dividends by our standards, the annual dividend amount must have increased steadily for at least the last 5 years.
Dividend yield of Pharming Group vs. the sector
The company's dividend yield is compared to the industry average to determine its positioning.
Imagine you have a list of dividend yields for different companies in an industry. If you look for the "top 25%% percentile", you will find a number. This number tells you that the top 25%% of the companies with the highest dividends have a yield higher than that number.
On the other hand, the "top 75%% percentile" shows you another number, which tells you that 75%% of the companies have a higher yield than that number, thus showing a more common and less high yield.
Dividend yield history in Pharming Group
For a company to have stable dividends by our standards, it is vital that it has not had an annual decline of more than 10% over the previous year.
Dividend history of Pharming Group
Pharming Group has never distributed dividends, so it has an empty dividend history.
Pharming Group dividend capture strategy
Information about Pharming Group
Pharming Group N.V., is a company with a worldwide presence dedicated to the biopharmaceutical sector, especially in the research and creation of treatments for rare or uncommon, debilitating diseases with a high mortality rate.
It is headquartered in Leiden, the Netherlands, and New Jersey, USA, but serves approximately 30 markets in Europe, the Middle East, North America, Africa and Asia, with more than 300 employees.
The group focuses on commercializing therapies based on protein replacement, as well as precision medicines, having partners at any level or stakeholder, from patients, healthcare professionals, employees, small laboratories, suppliers, external shareholders, among others.
Among its most representative drugs are RUCONEST® (conestat alfa) and JOENJA® (leniolisib), both approved by the EMA (European Medicines Agency) for marketing in Europe, by the FDA (Food and Drug Administration) for the United States and by the MHRA (Medicines and Healthcare products Regulatory Agency) for the United Kingdom.
Their technological platform is mainly based on the use of rhC1INH, although they are working on the development or acquisition of other methods to be used in their processes, in addition they also have in their platform as part of their services the monitoring and opportunity to report any adverse event, trying to comply with the global health care requirements and to update their products.
In addition, they are developing programs for the treatment of ADPS (sticky platelet syndrome), which is an abnormal, genetic and progressive immunodeficiency, as well as the research, creation and commercialization of OTL-105, a gene therapy that acts with stem cells to treat hereditary angioedema (HAE), which is being developed in collaboration with Orchard Therapeutics.
Frequently asked questions about Pharming Group dividends
Pharming Group is listed on the Bolsa de Amsterdam and is part of the ASCX.
Pharming Group has the Ticker or stock code PHARM.
Pharming Group belongs to the Health Care sector and the Biotechnology industry.
The CEO of Pharming Group in 2023 is Dr. Sijmen de Vries M.B.A., M.D..
At this moment, the value of a Pharming Group share is 1.08€.
Pharming Group does not have a growing dividend program. Dividends have not shown a steady growth in the last 5 years.